Tiziana Life Sciences Ltd

Tiziana Life Sciences is a small-cap clinical-stage biotech developing intranasal foralumab for multiple sclerosis and other autoimmune diseases — a genuine binary clinical setup approaching a readout. Down 41% YTD and 53% T12M, sitting at only 2% of the 52-week range with continued Executive Chairman insider buying.

The setup is a pre-revenue biotech at genuine binary catalyst point:

• The Phase 2 INFORM-MS dosing completion is a real catalyst-approach: dosing the last patient in the Phase 2 multiple sclerosis trial sets up a clinical readout in the coming quarters — that's the definition of a binary catalyst for a pre-revenue biotech.
• The Executive Chairman purchase is unusually constructive: Ivor Elrifi filing initial Form 3 as CEO/Director and Tiziana announcing a separate Executive Chairman purchase is exactly the kind of concentrated insider conviction signal that shows up before positive clinical readouts — it's not a guarantee but it's a real signal.
• The financials show the pre-commercial reality: essentially zero revenue with EPS ranging $-0.10 to $-0.22, consensus FY26 EPS of $-0.16 — the equity is entirely optionality on the foralumab clinical program.

The Sept 18 print will provide operational updates but the real drivers are the Phase 2 INFORM-MS data readout timing and any additional autoimmune-indication expansion. Handle as a small-position binary catalyst play — the insider buying is the confirming signal, but position sizing must reflect the pre-commercial character and the -53% T12M tape damage.